ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 171 filers reported holding ESPERION THERAPEUTICS INC NE in Q4 2022. The put-call ratio across all filers is 0.24 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $433,178 | -17.2% | 195,125 | 0.0% | 0.05% | -18.2% |
| Q1 2024 | $522,935 | -10.4% | 195,125 | 0.0% | 0.07% | -17.5% |
| Q4 2023 | $583,424 | +205.1% | 195,125 | 0.0% | 0.08% | +175.9% |
| Q3 2023 | $191,223 | -29.5% | 195,125 | 0.0% | 0.03% | -25.6% |
| Q2 2023 | $271,224 | -12.6% | 195,125 | 0.0% | 0.04% | -18.8% |
| Q1 2023 | $310,249 | +391.8% | 195,125 | +1827.2% | 0.05% | +380.0% |
| Q4 2022 | $63,079 | -7.2% | 10,125 | 0.0% | 0.01% | -16.7% |
| Q3 2022 | $68,000 | +4.6% | 10,125 | 0.0% | 0.01% | +9.1% |
| Q2 2022 | $65,000 | +38.3% | 10,125 | 0.0% | 0.01% | +83.3% |
| Q1 2022 | $47,000 | -7.8% | 10,125 | 0.0% | 0.01% | 0.0% |
| Q4 2021 | $51,000 | -58.2% | 10,125 | 0.0% | 0.01% | -64.7% |
| Q3 2021 | $122,000 | -43.0% | 10,125 | 0.0% | 0.02% | -39.3% |
| Q2 2021 | $214,000 | -24.6% | 10,125 | 0.0% | 0.03% | -30.0% |
| Q1 2021 | $284,000 | +8.0% | 10,125 | 0.0% | 0.04% | -2.4% |
| Q4 2020 | $263,000 | -30.1% | 10,125 | 0.0% | 0.04% | -39.7% |
| Q3 2020 | $376,000 | -27.6% | 10,125 | 0.0% | 0.07% | -30.6% |
| Q2 2020 | $519,000 | +62.2% | 10,125 | 0.0% | 0.10% | +34.2% |
| Q1 2020 | $320,000 | -46.9% | 10,125 | 0.0% | 0.07% | -28.4% |
| Q4 2019 | $603,000 | +62.1% | 10,125 | 0.0% | 0.10% | +50.0% |
| Q3 2019 | $372,000 | -21.0% | 10,125 | 0.0% | 0.07% | -19.0% |
| Q2 2019 | $471,000 | +16.0% | 10,125 | 0.0% | 0.08% | +13.5% |
| Q1 2019 | $406,000 | -12.9% | 10,125 | 0.0% | 0.07% | -23.7% |
| Q4 2018 | $466,000 | -5.7% | 10,125 | -9.0% | 0.10% | +15.5% |
| Q3 2018 | $494,000 | -16.6% | 11,125 | -26.4% | 0.08% | -20.8% |
| Q2 2018 | $592,000 | -26.5% | 15,125 | +36.0% | 0.11% | -25.9% |
| Q1 2018 | $805,000 | -6.8% | 11,125 | -15.2% | 0.14% | -4.0% |
| Q4 2017 | $864,000 | +31.3% | 13,125 | 0.0% | 0.15% | +25.2% |
| Q3 2017 | $658,000 | – | 13,125 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Boxer Capital, LLC | 1,275,000 | $45,020,000 | 9.84% |
| Aviva Holdings Ltd. | 340,100 | $12,009,000 | 5.60% |
| Aisling Capital LLC | 837,125 | $29,559,000 | 5.38% |
| RA Capital Management | 704,701 | $24,883,000 | 3.05% |
| Rhenman & Partners Asset Management AB | 543,347 | $19,186,000 | 3.04% |
| BB BIOTECH AG | 1,408,542 | $49,736,000 | 1.63% |
| Antipodean Advisors LLC | 91,000 | $3,213,000 | 1.57% |
| Iguana Healthcare Management, LLC | 75,000 | $2,648,000 | 1.31% |
| Crawford Lake Capital Management, LLC | 93,551 | $3,303,000 | 1.31% |
| FT Options LLC | 22,834 | $806,000 | 1.06% |